THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)

Exclusion Criteria

• •1. Refusal or inability (lack of capacity) to give informed consent.
• •2. Average alcohol ingestion greater than 21/14 units/week (males/females) in the preceding 6 months or history of sustained excessive consumption of alcohol in past 5 years.
• •3. History or presence of Type 1 diabetes mellitus.
• •4. Presence of any other form of chronic liver disease except NAFLD
• •5. Recent (within 12 months) or concomitant use of agents known to cause hepatic steatosis (long-term systemic corticosteroids \[\>10 days\], amiodarone, methotrexate, tamoxifen, tetracycline, high dose oestrogens, valproic acid).
• •6. Any contra-indication to liver biopsy.
• •7. Recent (within 3 months) change in dose/regimen or introduction of Vitamin E (at a dose ≥400 IU/day), betaine, s-adenosyl methionine, ursodeoxycholic acid, silymarin or pentoxifylline.
• •8. Non-French speaking/unable to access an interpreter.
• •9. Patients judged by the investigator to be unsuitable for inclusion in the study (e.g. judged by the physician as unlikely to be compliant with the study protocol).
• •10. Pregnant or breastfeeding women
• •11. Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom